Free Trial
ASX:RCE

Recce Pharmaceuticals (RCE) Stock Price, News & Analysis

Recce Pharmaceuticals logo

About Recce Pharmaceuticals Stock (ASX:RCE)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
630,087 shs
Average Volume
N/A
Market Capitalization
A$104.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive RCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recce Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCE Stock News Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Headlines

RCE Stock Analysis - Frequently Asked Questions

Recce Pharmaceuticals Ltd (ASX:RCE) released its quarterly earnings results on Wednesday, February, 27th. The company reported ($0.01) EPS for the quarter. Recce Pharmaceuticals had a negative net margin of 741.65% and a positive trailing twelve-month return on equity of 392.94%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Recce Pharmaceuticals investors own include ASE Technology (ASX), FlexiGroup Limited (FXL.AX) (FXL), Prima BioMed (IMMP), Mavenir (MVNR), Cronos Group (CRON), Cree (CREE) and Caladrius Biosciences (CLBS).

Company Calendar

Last Earnings
2/27/2019
Today
7/12/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:RCE
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
A($0.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-A$17.66 million
Net Margins
-741.65%
Pretax Margin
N/A
Return on Equity
392.94%
Return on Assets
-238.11%

Debt

Debt-to-Equity Ratio
-8.52
Current Ratio
0.34
Quick Ratio
4.81

Sales & Book Value

Annual Sales
A$5.03 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
13.57
Book Value
A($0.05) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
231,870,000
Free Float
N/A
Market Cap
A$104.34 million
Optionable
Not Optionable
Beta
1.05
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (ASX:RCE) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners